Morphic to present positive emerald-1 phase 2a data for morf-057 in patients with moderate to severe ulcerative colitis in abstract for uegw 2023

-orally administered morf-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-
MORF Ratings Summary
MORF Quant Ranking